Clinical Trial: Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non-small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Open-label Study to Determine the Central Nervous System Efficacy of Capmatinib in NSCLC Patients With Brain Metastases With cfDNA Positive MET Alterations
Brief Summary:
This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or MET?ex14 detected on cfDNA.
Read more